Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FARSHID DAYYANI

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1376710434
CMS profile
62653
Location
ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$230,104.67

333 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Sirtex Medical Inc $61,021.83 120
Exelixis Inc. $55,051.27 58
EISAI INC. $50,407.83 80
Ipsen Biopharmaceuticals, Inc $31,644.86 32
Amgen Inc. $19,284.84 32
Foundation Medicine, Inc. $10,750.00 6
Ipsen Bioscience Inc $1,720.02 3
Genentech USA, Inc. $126.78 1
Array BioPharma Inc. $97.24 1

Page 5 of 7; records 201–250 of 333 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FARSHID DAYYANI

NPI 1376710434 · CMS profile ID 62653

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 7; records 201–250 of 333 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376710434?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FARSHID DAYYANI, NPI 1376710434, CMS profile ID 62653. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 333 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376710434?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). FARSHID DAYYANI, NPI 1376710434, CMS profile ID 62653. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 333 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376710434?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
FARSHID DAYYANI, NPI 1376710434, CMS profile ID 62653, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 7; records 201–250 of 333 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1376710434?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

333 matching records · $230,104.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 333 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 333.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sirtex Medical Inc $21.3804/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664715 CMS
Sirtex Medical Inc $4,500.0004/24/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664757 CMS
Sirtex Medical Inc $121.5304/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698370105 CMS
Sirtex Medical Inc $701.0404/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664575 CMS
Sirtex Medical Inc $9.0004/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664577 CMS
Sirtex Medical Inc $329.7704/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664619 CMS
Sirtex Medical Inc $20.0004/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664645 CMS
Sirtex Medical Inc $15.6604/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664647 CMS
Sirtex Medical Inc $17.9604/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664649 CMS
Sirtex Medical Inc $7.3404/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664709 CMS
Sirtex Medical Inc $15.0404/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664711 CMS
Sirtex Medical Inc $12.9704/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664713 CMS
Foundation Medicine, Inc. $3,000.0004/18/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675548169 CMS
Eisai Inc. $1,000.0004/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703229941 CMS
Eisai Inc. $109.6304/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703229995 CMS
Eisai Inc. $3,125.0004/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703229997 CMS
Eisai Inc. $227.5904/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703229999 CMS
Eisai Inc. $617.1604/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703230001 CMS
Eisai Inc. $293.4104/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703230003 CMS
Eisai Inc. $11.6304/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703230005 CMS
Eisai Inc. $16.2404/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703230007 CMS
Eisai Inc. $20.0004/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703230009 CMS
Sirtex Medical Inc $141.1204/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698370097 CMS
Sirtex Medical Inc $4,500.0004/11/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664755 CMS
Amgen Inc. $15.4504/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662342447 CMS
Amgen Inc. $20.0004/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662342449 CMS
Amgen Inc. $20.4504/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662342455 CMS
Amgen Inc. $32.7804/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662342457 CMS
Amgen Inc. $4.0004/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662342459 CMS
Eisai Inc. $625.0004/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703229957 CMS
Amgen Inc. $2,600.0004/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662342451 CMS
Amgen Inc. $866.0004/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662342453 CMS
Sirtex Medical Inc $636.9903/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664569 CMS
Sirtex Medical Inc $9.0003/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664571 CMS
Sirtex Medical Inc $62.0003/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664573 CMS
Eisai Inc. $122.2803/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703230029 CMS
Eisai Inc. $3,125.0003/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703230031 CMS
Eisai Inc. $18.5603/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703230033 CMS
Eisai Inc. $4.0003/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703230035 CMS
Foundation Medicine, Inc. $2,000.0003/28/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675548167 CMS
Amgen Inc. $120.8103/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662342441 CMS
Amgen Inc. $266.0703/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662342445 CMS
Sirtex Medical Inc $80.0603/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664641 CMS
Sirtex Medical Inc $20.0003/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664643 CMS
Sirtex Medical Inc $12.9603/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664703 CMS
Sirtex Medical Inc $12.4803/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664705 CMS
Sirtex Medical Inc $6.1903/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704664707 CMS
Exelixis Inc. $5,280.0003/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686542849 CMS
Eisai Inc. $35.9603/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703229939 CMS
Eisai Inc. $95.3703/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703229981 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $230,104.67 333
PY2020 $62,933.85 60
PY2021 $47,273.43 31
PY2022 $58,354.54 43
PY2023 $200,662.13 184
PY2024 $266,862.51 159
PY2025 $289,318.48 165

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,721,730.22 189
PY2024 Principal investigator $2,129,801.10 84
PY2023 Principal investigator $1,178,329.48 52
PY2022 Recipient $400.01 1
PY2022 Principal investigator $1,158,103.64 40
PY2021 Principal investigator $2,063,941.97 51
PY2020 Recipient $8,306.48 5
PY2020 Principal investigator $1,850,901.21 79
PY2019 Principal investigator $1,109,962.19 111

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

189 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $615.12 12/31/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults with Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1202425046
Principal investigator 1 Genentech, Inc. $26,208.00 12/29/2025 Covered Recipient Teaching Hospital
Fountain Valley Reg Medical Center
PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC No dispute reported 06/30/2026 1211544369
Principal investigator 1 Genentech, Inc. $828.00 12/05/2025 Covered Recipient Teaching Hospital
Fountain Valley Reg Medical Center
PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC No dispute reported 06/30/2026 1211544373
Principal investigator 1 ABBVIE INC. $578.53 12/04/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202425021
Principal investigator 1 Boehringer Ingelheim International GmbH $4,010.00 12/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737898
Principal investigator 1 Boehringer Ingelheim International GmbH $5,020.00 12/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737900
Principal investigator 1 Boehringer Ingelheim International GmbH $4,010.00 12/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737902
Principal investigator 1 Boehringer Ingelheim International GmbH $528.00 12/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737904
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 12/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737906
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737896
Principal investigator 1 Boehringer Ingelheim International GmbH $16,896.00 11/30/2025 Non-covered Recipient Entity
University Of California Irvine
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220650237
Principal investigator 1 Amgen Inc. $25,091.00 11/25/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301) No dispute reported 06/30/2026 1246638568
Principal investigator 1 Boehringer Ingelheim International GmbH $288.49 11/19/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737908
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 11/19/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737910
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 11/19/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737912
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 11/19/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737914
Principal investigator 1 Boehringer Ingelheim International GmbH $122.14 11/19/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737916
Principal investigator 1 Boehringer Ingelheim International GmbH $59.00 11/19/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737918
Principal investigator 1 Boehringer Ingelheim International GmbH $20.44 11/19/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737920
Principal investigator 1 Ipsen Bioscience Inc. $1,571.00 11/18/2025 Non-covered Recipient Entity
Uci Health Chao Family Comprehensive Cancer Center
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176546185
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,500.00 11/14/2025 Non-covered Recipient Entity
SABAI LLC
A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma No dispute reported 06/30/2026 1185549213
Principal investigator 1 Ipsen Bioscience Inc. $15,496.00 11/14/2025 Non-covered Recipient Entity
Uci Health Chao Family Comprehensive Cancer Center
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176546187
Principal investigator 1 Ipsen Bioscience Inc. $18,194.00 11/13/2025 Non-covered Recipient Entity
Uci Health Chao Family Comprehensive Cancer Center
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176546189
Principal investigator 1 Exelixis Inc. $691.20 11/07/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222378220
Principal investigator 1 ABBVIE INC. $2,403.07 11/05/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424984
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,690.00 11/05/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Durvalumab or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1 No dispute reported 06/30/2026 1185549203
Principal investigator 1 Boehringer Ingelheim International GmbH $5,020.00 11/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737874
Principal investigator 1 Boehringer Ingelheim International GmbH $6,042.00 11/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737876
Principal investigator 1 Boehringer Ingelheim International GmbH $528.00 11/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737878
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 11/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737880
Principal investigator 1 Boehringer Ingelheim International GmbH $106.00 11/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737882
Principal investigator 1 Boehringer Ingelheim International GmbH $106.00 11/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737884
Principal investigator 1 Boehringer Ingelheim International GmbH $33.00 11/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737886
Principal investigator 1 Boehringer Ingelheim International GmbH $33.00 11/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737888
Principal investigator 1 Boehringer Ingelheim International GmbH $58.00 11/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737890
Principal investigator 1 Boehringer Ingelheim International GmbH $3,054.00 11/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737892
Principal investigator 1 Boehringer Ingelheim International GmbH $4,537.00 11/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737894
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737872
Principal investigator 1 ABBVIE INC. $8,745.00 10/31/2025 Covered Recipient Teaching Hospital
LANGLEY PORTER PSYCHIATRIC HOSPITAL
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) No dispute reported 06/30/2026 1202414308
Principal investigator 1 Boehringer Ingelheim International GmbH $9,380.00 10/31/2025 Non-covered Recipient Entity
University Of California Irvine
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220650225
Principal investigator 1 Boehringer Ingelheim International GmbH $7,993.88 10/31/2025 Non-covered Recipient Entity
University Of California Irvine
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220650227
Principal investigator 1 Boehringer Ingelheim International GmbH $11,663.52 10/31/2025 Non-covered Recipient Entity
University Of California Irvine
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220650229
Principal investigator 1 Boehringer Ingelheim International GmbH $17,443.80 10/31/2025 Non-covered Recipient Entity
University Of California Irvine
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220650231
Principal investigator 1 Boehringer Ingelheim International GmbH $40,332.60 10/31/2025 Non-covered Recipient Entity
University Of California Irvine
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220650233
Principal investigator 1 Boehringer Ingelheim International GmbH $66,931.92 10/31/2025 Non-covered Recipient Entity
University Of California Irvine
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220650235
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $61,395.64 10/31/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220997784
Principal investigator 1 Genentech, Inc. $13,453.20 10/22/2025 Covered Recipient Teaching Hospital
Fountain Valley Reg Medical Center
PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC No dispute reported 06/30/2026 1211544365
Principal investigator 1 ABBVIE INC. $22,912.56 10/17/2025 Covered Recipient Teaching Hospital
LANGLEY PORTER PSYCHIATRIC HOSPITAL
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) No dispute reported 06/30/2026 1202414300
Principal investigator 1 PFIZER INC. $1,327.92 10/14/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228712606
Principal investigator 1 ABBVIE INC. $2,403.07 10/09/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424913
Principal investigator 1 Boehringer Ingelheim International GmbH $3,051.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737840
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737842
Principal investigator 1 Boehringer Ingelheim International GmbH $106.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737844
Principal investigator 1 Boehringer Ingelheim International GmbH $1,942.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737846
Principal investigator 1 Boehringer Ingelheim International GmbH $33.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737848
Principal investigator 1 Boehringer Ingelheim International GmbH $58.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737850
Principal investigator 1 Boehringer Ingelheim International GmbH $1,942.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737852
Principal investigator 1 Boehringer Ingelheim International GmbH $347.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737854
Principal investigator 1 Boehringer Ingelheim International GmbH $347.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737856
Principal investigator 1 Boehringer Ingelheim International GmbH $6,042.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737858
Principal investigator 1 Boehringer Ingelheim International GmbH $528.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737860
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737862
Principal investigator 1 Boehringer Ingelheim International GmbH $3,128.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737864
Principal investigator 1 Boehringer Ingelheim International GmbH $6,110.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737866
Principal investigator 1 Boehringer Ingelheim International GmbH $1,621.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737868
Principal investigator 1 Boehringer Ingelheim International GmbH $528.00 10/02/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737870
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737838
Principal investigator 1 Genentech, Inc. $12,091.00 10/01/2025 Covered Recipient Teaching Hospital
Langley Porter Psychiatric Hospital
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211548157
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $71,628.25 09/30/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220997782
Principal investigator 1 Exelixis Inc. $1,278.00 09/19/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222378216
Principal investigator 1 ABBVIE INC. $46,209.68 09/12/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) No dispute reported 06/30/2026 1202424523
Principal investigator 1 ABBVIE INC. $11,513.99 09/05/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424895
Principal investigator 1 Exelixis Inc. $1,330.20 09/05/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222378218
Principal investigator 1 ABBVIE INC. $4,245.09 09/04/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424883
Principal investigator 1 Boehringer Ingelheim International GmbH $3,054.00 09/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737814
Principal investigator 1 Boehringer Ingelheim International GmbH $4,537.00 09/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737816
Principal investigator 1 Boehringer Ingelheim International GmbH $4,022.00 09/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737818
Principal investigator 1 Boehringer Ingelheim International GmbH $6,648.00 09/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737820
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 09/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737822
Principal investigator 1 Boehringer Ingelheim International GmbH $106.00 09/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737824
Principal investigator 1 Boehringer Ingelheim International GmbH $3,054.00 09/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737826
Principal investigator 1 Boehringer Ingelheim International GmbH $4,537.00 09/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737828
Principal investigator 1 Boehringer Ingelheim International GmbH $4,058.00 09/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737830
Principal investigator 1 Boehringer Ingelheim International GmbH $4,537.00 09/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737832
Principal investigator 1 Boehringer Ingelheim International GmbH $6,110.00 09/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737834
Principal investigator 1 Boehringer Ingelheim International GmbH $1,621.00 09/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737836
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737774
Principal investigator 1 Boehringer Ingelheim International GmbH $24,681.25 08/31/2025 Non-covered Recipient Entity
University Of California Irvine
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220650223
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $41,499.47 08/27/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
Fruquintinib No dispute reported 06/30/2026 1223270376
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,240.00 08/27/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
Fruquintinib No dispute reported 06/30/2026 1223270378
Principal investigator 1 ABBVIE INC. $578.53 08/06/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424843
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737772
Principal investigator 1 Boehringer Ingelheim International GmbH $6,648.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737778
Principal investigator 1 Boehringer Ingelheim International GmbH $1,942.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737780
Principal investigator 1 Boehringer Ingelheim International GmbH $347.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737782
Principal investigator 1 Boehringer Ingelheim International GmbH $6,648.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737784
Principal investigator 1 Boehringer Ingelheim International GmbH $4,022.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737786
Principal investigator 1 Boehringer Ingelheim International GmbH $3,128.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737788
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737790
Principal investigator 1 Boehringer Ingelheim International GmbH $106.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737792
Principal investigator 1 Boehringer Ingelheim International GmbH $1,942.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737794
Principal investigator 1 Boehringer Ingelheim International GmbH $347.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737796
Principal investigator 1 Boehringer Ingelheim International GmbH $4,022.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737798
Principal investigator 1 Boehringer Ingelheim International GmbH $3,128.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737800
Principal investigator 1 Boehringer Ingelheim International GmbH $4,537.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737802
Principal investigator 1 Boehringer Ingelheim International GmbH $6,110.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737804
Principal investigator 1 Boehringer Ingelheim International GmbH $1,621.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737806
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737808
Principal investigator 1 Boehringer Ingelheim International GmbH $106.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737810
Principal investigator 1 Boehringer Ingelheim International GmbH $58.00 08/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737812
Principal investigator 1 Exelixis Inc. $691.20 07/18/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222378214
Principal investigator 1 ABBVIE INC. $13,173.20 07/08/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424762
Principal investigator 1 ABBVIE INC. $4,806.14 07/02/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424736
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737776
Principal investigator 1 Boehringer Ingelheim International GmbH $2,448.60 06/30/2025 Non-covered Recipient Entity
University Of California Irvine
A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. No dispute reported 06/30/2026 1220650221
Principal investigator 1 Boehringer Ingelheim International GmbH $509.10 06/24/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737742
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 06/24/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737744
Principal investigator 1 Boehringer Ingelheim International GmbH $539.46 06/24/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737746
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 06/24/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737748
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 06/24/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737750
Principal investigator 1 Boehringer Ingelheim International GmbH $143.00 06/24/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737752
Principal investigator 1 Boehringer Ingelheim International GmbH $30.66 06/24/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737754
Principal investigator 1 PFIZER INC. $5,083.18 06/23/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228830303
Principal investigator 1 Exelixis Inc. $639.00 06/20/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222378212
Principal investigator 1 PFIZER INC. $5,804.38 06/16/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228830296
Principal investigator 1 Genentech, Inc. $8,264.10 06/11/2025 Covered Recipient Teaching Hospital
Fountain Valley Reg Medical Center
PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC No dispute reported 06/30/2026 1211544351
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737734
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 05/27/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737736
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 05/27/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737738
Principal investigator 1 Boehringer Ingelheim International GmbH $5.84 05/27/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737740
Principal investigator 1 Boehringer Ingelheim International GmbH $67.88 05/27/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737770
Principal investigator 1 Genentech, Inc. $22,374.00 05/21/2025 Covered Recipient Teaching Hospital
Fountain Valley Reg Medical Center
PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC No dispute reported 06/30/2026 1211544356
Principal investigator 1 Exelixis Inc. $1,969.20 05/16/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222378208
Principal investigator 1 Genentech, Inc. $3,834.00 05/16/2025 Covered Recipient Teaching Hospital
Fountain Valley Reg Medical Center
PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC No dispute reported 06/30/2026 1211544360
Principal investigator 1 ABBVIE INC. $21,424.66 05/14/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424698
Principal investigator 1 ABBVIE INC. $22,570.61 05/14/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424703
Principal investigator 1 PFIZER INC. $10,940.00 05/13/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228827135
Principal investigator 1 PFIZER INC. $43,996.68 05/13/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228827141
Principal investigator 1 PFIZER INC. $10,940.00 05/12/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228825863
Principal investigator 1 PFIZER INC. $43,996.68 05/12/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228825866
Principal investigator 1 Exelixis Inc. $5,912.00 05/09/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222378206
Principal investigator 1 ABBVIE INC. $23,311.31 05/08/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424690
Principal investigator 1 ABBVIE INC. $10,358.48 05/07/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424679
Principal investigator 1 Exelixis Inc. $77,084.79 05/05/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Phase 2 Study of Cabozantinib Combined With Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC) Who Are Not Candidates for Curative Intent Treatment No dispute reported 06/30/2026 1222378256
Principal investigator 1 Merck Sharp & Dohme LLC $5,764.00 05/05/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastro No dispute reported 06/30/2026 1232927381
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737732
Principal investigator 1 Boehringer Ingelheim International GmbH $339.40 04/23/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737756
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 04/23/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737758
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 04/23/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737760
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 04/23/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737762
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 04/23/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737764
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 04/23/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737766
Principal investigator 1 Boehringer Ingelheim International GmbH $23.36 04/23/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737768
Principal investigator 1 Exelixis Inc. $691.20 04/21/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222378210
Principal investigator 1 Ipsen Bioscience Inc. $20,090.84 04/18/2025 Non-covered Recipient Entity
Uci Health Chao Family Comprehensive Cancer Center
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176546183
Principal investigator 1 Amgen Inc. $5,797.84 04/15/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression No dispute reported 06/30/2026 1246638570
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737730
Principal investigator 1 Exelixis Inc. $12,970.00 03/31/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 1 Study of the Combination of Cabozantinib With Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Adenocarcinoma (mCRC) No dispute reported 06/30/2026 1222378226
Principal investigator 1 AstraZeneca UK Limited $69,812.16 03/21/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 Combination with Durvalumab and Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1185549209
Principal investigator 1 Exelixis Inc. $1,330.20 03/21/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222378198
Principal investigator 1 Genentech, Inc. $6,552.00 03/19/2025 Covered Recipient Teaching Hospital
Fountain Valley Reg Medical Center
PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC No dispute reported 06/30/2026 1211544348
Principal investigator 1 Exelixis Inc. $10,330.00 03/17/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Phase 2 Study of Cabozantinib Combined With Pembrolizumab in Metastatic or Recurrent Gastric and Gastroesophageal Adenocarcinoma (mGC) No dispute reported 06/30/2026 1222378222
Principal investigator 1 ABBVIE INC. $5,017.50 03/07/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424654
Principal investigator 1 AstraZeneca Pharmaceuticals LP $633,535.71 03/05/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase II Open-label Multi-centre Study to Evaluate Safety Tolerability Efficacy PK and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 182 No dispute reported 06/30/2026 1185549211
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737728
Principal investigator 1 AstraZeneca Pharmaceuticals LP $105,067.64 02/28/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 1185549215
Principal investigator 1 Exelixis Inc. $6,550.04 02/24/2025 Covered Recipient Teaching Hospital
Uci Medical Center
Phase 2 Study of Cabozantinib Combined With Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC) Who Are Not Candidates for Curative Intent Treatment No dispute reported 06/30/2026 1222378230
Principal investigator 1 Exelixis Inc. $7,380.00 02/21/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222378204
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,750.00 02/13/2025 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES LLC
A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma No dispute reported 06/30/2026 1185549207
Principal investigator 1 ABBVIE INC. $663.07 02/06/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424624
Principal investigator 1 PFIZER INC. $21,059.34 02/03/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228831773
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737726
Principal investigator 1 AstraZeneca UK Limited $338,016.02 01/29/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE) No dispute reported 06/30/2026 1185549199
Principal investigator 1 Exelixis Inc. $10,481.00 01/29/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222378202
Principal investigator 1 Exelixis Inc. $11,646.00 01/24/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222378200
Principal investigator 1 Exelixis Inc. $21,316.81 01/21/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 1 Study of the Combination of Cabozantinib With Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Adenocarcinoma (mCRC) No dispute reported 06/30/2026 1222378224
Principal investigator 1 Exelixis Inc. $15,620.28 01/21/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase 1 Study of the Combination of Cabozantinib With Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Adenocarcinoma (mCRC) No dispute reported 06/30/2026 1222378232
Principal investigator 1 AstraZeneca Pharmaceuticals LP $75,894.03 01/10/2025 Covered Recipient Teaching Hospital
Uci Medical Center
A Phase III,Randomized,Double Blind,Placebo Controlled,Multicenter,Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment in Adult Participants After Resection of Biliary Tract Cancer with Curative Intent Artemide Biliary01 No dispute reported 06/30/2026 1185549201
Principal investigator 1 AstraZeneca Pharmaceuticals LP $176,253.58 01/10/2025 Covered Recipient Teaching Hospital
Uci Medical Center
This Phase II, open-label, uncontrolled, multicentre study evaluating the preliminary efficacy and safety of Volrustomig or Rilvegostomig as monotherapy (MONO) No dispute reported 06/30/2026 1185549205
Principal investigator 1 Boehringer Ingelheim International GmbH $3,960.00 01/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737708
Principal investigator 1 Boehringer Ingelheim International GmbH $3,500.00 01/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737710
Principal investigator 1 Boehringer Ingelheim International GmbH $2,442.00 01/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737712
Principal investigator 1 Boehringer Ingelheim International GmbH $22,750.00 01/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737714
Principal investigator 1 Boehringer Ingelheim International GmbH $1,320.00 01/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737716
Principal investigator 1 Boehringer Ingelheim International GmbH $2,750.00 01/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737718
Principal investigator 1 Boehringer Ingelheim International GmbH $2,240.00 01/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737720
Principal investigator 1 Boehringer Ingelheim International GmbH $2,275.00 01/03/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737722
Principal investigator 1 ABBVIE INC. $2,403.07 01/02/2025 Covered Recipient Teaching Hospital
UCI MEDICAL CENTER
M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202424600
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
University Of California At Irvine Health Chao Family Comprehensive Cancer Center
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220737724